Advanced Filters
noise
Found 811 clinical trials
C Cennet Sena Parlatan, pHD Cand

The Effects of Specific tDCS on Cognition in MCI

INTRODUCTION Mild cognitive impairment (MCI) is a critical transitional stage in dementia related disorders. Dorsolateral prefrontal cortex (DLPFC), and the lateral parietal (LPC) cortex are subjected to neuropathological changes in MCI. Parietal memory network (PMN) integrity alterations and default mode network (DMN) alterations also occur in MCI. Transcranial direct current …

45 - 80 years of age All Phase N/A
Y Youmao Zheng, MM

An Exploratory Study to Confirm Efficacy of Modified Deep Cervical Lymphovenous Anastomosis (LVA) in Alzheimer's Disease/ Parkinson's Disease

Alzheimer's disease (AD) and Parkinson's disease (PD) are characterized by pathological protein accumulation in the brain-Aβ/tau in AD and α-synuclein in PD. Recent studies have indicated that age-related lymphatic vessel atrophy compromises the metabolic clearance capacity of meningeal lymphatic vessels, potentially disrupting the equilibrium between production and clearance of Aβ/α-synuclein, …

50 - 80 years of age All Phase N/A

Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986368, for the Treatment of Agitation in Participants With Alzheimer's Disease

This is a study to evaluate the efficacy, safety, and tolerability of BMS-986368, a FAAH/MAGL inhibitor, for the treatment of agitation in participants with Alzheimer's Disease.

55 - 90 years of age All Phase 2
B Bei Zhang

Advantage of Cerebellar Transcranial Magnetic Stimulation in Alzheimer's Diseases (ACT-AD)

Alzheimer's Disease (AD) is the primary cause of dementia, with its prominent feature being cognitive decline. The cerebellum plays a crucial role in cognitive processing, making it a potential target for therapeutic intervention. This study will be conducted to evaluate the efficacy and safety of cerebellar Intermittent theta-burst stimulation (CRB-iTBS) …

50 - 85 years of age All Phase N/A
L Lisbeth Marner

Brain Blood Flow and Sugar Transport in Alzheimer's Disease With and Without Diabetes - A Pilot Imaging Study

Alzheimer's disease is the most common cause of dementia and affects a growing number of older adults. Although harmful proteins build up in the brain, we still do not fully understand why some brain regions are affected earlier or more severely than others. Many people with Alzheimer's disease also have …

60 - 90 years of age All Phase N/A
X Xiaomeng Xu, Dr

Ruijin Neurobank of Alzheimer's Disease and Dementia

The goal of this observational study is to learn about neuroimage and biomarkers in the Alzheimer's continuum. The main questions it aims to answer are: How is the neurovascular coupling during AD pathogenesis? How is the pattern/mapping of alterations in AD biomarkers? Participants will be observed and visit the research …

50 - 90 years of age All Phase N/A
N Nadjia YOUNSI

Investigation of AlzHeimer's Predictors in Subjective Memory Complainers - Extension Study

A regional, single-center, prospective, observational academic cohort will follow subjects who previously participated in the INSIGHT study and who agree an extension of their follow-up in the INSIGHT-2 research for additional 5-6 years. An annual multimodal evaluation (cognitive, oculomotor, biological and neuroimaging) will be proposed in order to describe the …

70 - 95 years of age All Phase N/A
H Humberto Martinez, COT

OCT Angiography and NRAI in Dementia

The primary goals of this study are to use optical coherence tomography (OCT) angiography (blood vessel mapping) to: Detect retinal blood vessel and blood flow changes in participants with dementia. Detect amyloid protein deposits in the retinas of participants with dementia.

55 years of age All Phase N/A
I IMZI Nadia

Pilot Study on the Feasibility of Using Smartphone Data as a Diagnostic Marker for Alzheimer's Disease

This study will compare smartphone usage data between three groups of patients diagnosed with either a memory complaint, mild cognitive decline, or Alzheimer's disease.

60 years of age All Phase N/A

Study of Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of NIO752 in Early Alzheimer's Disease Participants

Phase 1b study to assess the pharmacodynamics, safety, tolerability, and pharmacokinetics of NIO752 in patients with early Alzheimer's disease (AD)

30 - 74 years of age All Phase 1

Simplify language using AI